SF3B1 and myelodysplastic syndrome: Therapeutic targeting of AS to treat cancer is a rapidly developing field49 with several types of SF3B1 inhibitors, such as E710750,51, an analog of pladienolide B, and H3B-880052 being evaluated for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)33,49,52.